- Merck's shares surged 75% in a year as analysts upgraded targets, despite a Q2 adjusted loss driven by $5.7B in one-time acquisition charges. - The "earnings collapse" stemmed from $2.43/share ...

Here's the mechanism that explains both the run and why the easy money is now spent. Regeneron records its share of Dupixent ...